These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Author response to comment on "Power of rare diseases: found in translation". Fishman MC Sci Transl Med; 2014 Mar; 6(228):228lr1. PubMed ID: 24648339 [TBL] [Abstract][Full Text] [Related]
7. Diabetes-Associated Mutations in Proinsulin Provide a "Molecular Rheostat" of Nascent Foldability. Dhayalan B; Weiss MA Curr Diab Rep; 2022 Feb; 22(2):85-94. PubMed ID: 35119630 [TBL] [Abstract][Full Text] [Related]
8. Clinical care and therapeutic trials in PLS. Floeter MK; Warden D; Lange D; Wymer J; Paganoni S; Mitsumoto H Amyotroph Lateral Scler Frontotemporal Degener; 2020 Nov; 21(sup1):67-73. PubMed ID: 33602017 [TBL] [Abstract][Full Text] [Related]
9. Impaired angiogenesis and extracellular matrix metabolism in autosomal-dominant hyper-IgE syndrome. Dmitrieva NI; Walts AD; Nguyen DP; Grubb A; Zhang X; Wang X; Ping X; Jin H; Yu Z; Yu ZX; Yang D; Schwartzbeck R; Dalgard CL; Kozel BA; Levin MD; Knutsen RH; Liu D; Milner JD; López DB; O'Connell MP; Lee CR; Myles IA; Hsu AP; Freeman AF; Holland SM; Chen G; Boehm M J Clin Invest; 2020 Aug; 130(8):4167-4181. PubMed ID: 32369445 [TBL] [Abstract][Full Text] [Related]
10. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma. Roufosse F Front Med (Lausanne); 2018; 5():49. PubMed ID: 29682504 [TBL] [Abstract][Full Text] [Related]
11. Emerging Opportunities for Target Discovery in Rare Cancers. Sharifnia T; Hong AL; Painter CA; Boehm JS Cell Chem Biol; 2017 Sep; 24(9):1075-1091. PubMed ID: 28938087 [TBL] [Abstract][Full Text] [Related]
12. Opportunities and challenges in phenotypic drug discovery: an industry perspective. Moffat JG; Vincent F; Lee JA; Eder J; Prunotto M Nat Rev Drug Discov; 2017 Aug; 16(8):531-543. PubMed ID: 28685762 [TBL] [Abstract][Full Text] [Related]
13. Mitigating risk in academic preclinical drug discovery. Dahlin JL; Inglese J; Walters MA Nat Rev Drug Discov; 2015 Apr; 14(4):279-94. PubMed ID: 25829283 [TBL] [Abstract][Full Text] [Related]
14. Insights into the possible role of IFNG and IFNGR1 in Kala-azar and Post Kala-azar Dermal Leishmaniasis in Sudanese patients. Salih MA; Fakiola M; Abdelraheem MH; Younis BM; Musa AM; ElHassan AM; Blackwell JM; Ibrahim ME; Mohamed HS BMC Infect Dis; 2014 Dec; 14():662. PubMed ID: 25466928 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic targeting of cellular metabolism in cells with hyperactive mTORC1: a paradigm shift. Medvetz D; Priolo C; Henske EP Mol Cancer Res; 2015 Jan; 13(1):3-8. PubMed ID: 25298408 [TBL] [Abstract][Full Text] [Related]
16. Designing innovative therapies for neuropathic pain: pros and cons of target-based drug discovery. Inglese J J Peripher Nerv Syst; 2014 Oct; 19 Suppl 2(Suppl 2):S6-9. PubMed ID: 25269741 [No Abstract] [Full Text] [Related]
17. Integrative analysis of independent transcriptome data for rare diseases. Zhang Z; Hailat Z; Falk MJ; Chen XW Methods; 2014 Oct; 69(3):315-25. PubMed ID: 24981076 [TBL] [Abstract][Full Text] [Related]
18. Power of rare diseases: found in translation. Fishman MC Sci Transl Med; 2013 Sep; 5(201):201ps11. PubMed ID: 24005157 [TBL] [Abstract][Full Text] [Related]
19. Comment on "Power of rare diseases: found in translation". van der Meer JW; Simon A; Dinarello CA Sci Transl Med; 2014 Jan; 6(219):219le1. PubMed ID: 24431110 [TBL] [Abstract][Full Text] [Related]